金斯瑞生物科技(01548)：传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据

智通财经网11-05

智通财经APP讯，金斯瑞生物科技(01548)发布公告，于2024年11月5日，传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据，该试验对比CARVYKTI®(西达基奥仑赛，cilta-cel)与标准疗法(SoC)针对多发性骨髓瘤患者的治疗。研究评估了既往接受过 1–3线治疗且来那度胺耐药的患者，并将在2024年12月9日(星期一)下午5:45(太平洋...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2481836206?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-05 22:37","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2481836206","market":"hk","top_or_hot":-1,"title":"金斯瑞生物科技(01548)：传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据","media":"智通财经网","content":"<div>\n<p>智通财经APP讯，金斯瑞生物科技(01548)发布公告，于2024年11月5日，传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据，该试验对比CARVYKTI®(西达基奥仑赛，cilta-cel)与标准疗法(SoC)针对多发性骨髓瘤患者的治疗。研究评估了既往接受过 1–3线治疗且来那度胺耐药的患者，并将在2024年12月9日(星期一)下午5:45(太平洋...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1207173.html\">网页链接</a>\n\n</div>\n","source":"highlight_zhitongcaijin","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>金斯瑞生物科技(01548)：传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n金斯瑞生物科技(01548)：传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 22:37 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1207173.html><strong>智通财经网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，金斯瑞生物科技(01548)发布公告，于2024年11月5日，传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据，该试验对比CARVYKTI®(西达基奥仑赛，cilta-cel)与标准疗法(SoC)针对多发性骨髓瘤患者的治疗。研究评估了既往接受过 1–3线治疗且来那度胺耐药的患者，并将在2024年12月9日(星期一)下午5:45(太平洋...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1207173.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LEGN","symbol_name":"传奇生物","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1207173.html","article_id":"2481836206","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481836206","pubTimestamp":1730817421,"sourceInfo":{"source_id":"highlight_zhitongcaijin","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，金斯瑞生物科技 发布公告，于2024年11月5日，传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病阴性率的最新数据，该试验对比CARVYKTI与标准疗法针对多发性骨髓瘤患者的治疗。CARVYKTI是目前首个且唯一获批用于治疗既往至少接受过一线治疗的多发性骨髓瘤患者的靶向BCMA的CAR-T细胞疗法。CARVYKTI目前已在全球五个国家商业化，有超过4,000名患者使用。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LEGN":"传奇生物","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","01548":"金斯瑞生物科技","BK4505":"高瓴资本持仓","BK1141":"生命科学工具和服务","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK1576":"医药外包概念","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK4588":"碎股","BK1583":"高瓴概念"},"translate_title":"GenScript Biotech (01548): Legend Biotech announces that it will present updated data on minimal residual disease (MRD) negative rates in the Phase 3 CARTITUDE-4 trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":0.6,"LEGN":0.6},"content_text":"智通财经APP讯，金斯瑞生物科技(01548)发布公告，于2024年11月5日，传奇生物宣布将展示有关3期 CARTITUDE-4试验的微小残留病(MRD)阴性率的最新数据，该试验对比CARVYKTI®(西达基奥仑赛，cilta-cel)与标准疗法(SoC)针对多发性骨髓瘤患者的治疗。研究评估了既往接受过 1–3线治疗且来那度胺耐药的患者，并将在2024年12月9日(星期一)下午5:45(太平洋时间)于圣地亚哥举办的第66届美国血液学会年会上以口头报告形式公布。来自CARTITUDE-4的数据支持美国食品药品监督管理局及欧盟委员会在今年早些时候批准CARVYKTI®用于治疗复发或难治性多发性骨髓瘤成人患者，这些患者既往至少接受过一线治疗(LOT)，包括一种蛋白酶体抑制剂(PI)和一种免疫调节剂(IMiD)且对来那度胺耐药。CARVYKTI®是目前首个且唯一获批用于治疗既往至少接受过一线治疗的多发性骨髓瘤患者的靶向BCMA的CAR-T细胞疗法。CARVYKTI目前已在全球五个国家商业化，有超过4,000名患者使用。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481836206"}